Silo Pharma Collaborates with WuXi AppTec for Preclinical MS Research

Silo Pharma Inc. a biopharmaceutical company, has entered into a collaboration with WuXi AppTec to conduct preclinical research on a novel peptide, SPU-16, aimed at treating multiple sclerosis (MS). This partnership focuses on assessing the tissue specificity of SPU-16, which is designed to target inflamed tissues in the central nervous system, particularly within the spinal cord.

The study, managed by WuXi AppTec, will utilize an experimental autoimmune encephalomyelitis (EAE) model, a standard protocol in MS research, to evaluate the peptide’s effectiveness in targeting inflammation. Silo Pharma’s CEO, Eric Weisblum, expressed optimism about SPU-16’s potential to enhance current and future MS therapies while reducing drug toxicity.

Silo Pharma is also advancing other initiatives, including treatments for psychiatric disorders and chronic pain. Among its pipeline are an intranasal treatment for PTSD, a time-release ketamine implant for chronic pain, and an Alzheimer’s therapy. The company has secured an exclusive global license for its Alzheimer’s medication, SPC-14, and is conducting preclinical trials on its PTSD therapeutic, SPC-15.

On the financial front, Silo Pharma has announced a registered direct offering and private placement aiming to raise approximately $2 million, which will support working capital and general corporate purposes. Despite its small market capitalization of $6.05 million, the company boasts a high gross profit margin of 91.9%, signaling strong operational efficiency. However, the stock has experienced significant volatility, which may appeal to short-term investors but warrants caution for those seeking stability.

As Silo Pharma continues to explore novel therapeutics, its collaboration with WuXi AppTec marks a significant step forward in its efforts to address complex neurological conditions like MS.